Did Neuren have much of a choice in this situation? Wanting to avoid contractual interpretations, but I figure it makes sense to give Acadia the option of developing 2591 in Retts and Fragile-X so as to steer well clear of any competition issues that may arise that could contravene the agreement between Acadia and Neuren.
I'd imagine Acadia would be very upset if Neuren licensed 2591 for Retts and Fragile X to somebody else or they developed these themselves in direct competition to Acadia. You partnered with someone just for them to allow a superior drug to come in and decimate Daybue? I doubt it very much. I think this understanding is at the core of the arrangement between the two companies, so perhaps these indications were locked from the very beginning when trofinetide was licensed to Acadia.
NEU Price at posting:
$10.53 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)